Breaking News Instant updates and real-time market news.

ARRY

Array BioPharma

$46.42

16.83 (56.88%)

, PFE

Pfizer

$42.87

0.12 (0.28%)

07:37
06/18/19
06/18
07:37
06/18/19
07:37

Array BioPharma downgraded to Hold from Buy at SunTrust

SunTrust analyst Peter Lawson downgraded Array BioPharma (ARRY) to Hold but raised his price target to $48 from $32 after the company announced that it is being acquired by Pfizer (PFE) at that price. The analyst notes that the 79% premium to the company's last closing price looks like a "fair valuation" based on his analysis of past comps and his M&A valuation model. Lawson adds that the the deal is "encouraging" within the biotech space with positive implications for other potential acquisition targets such as Agios Pharmaceuticals (AGIO) and Mirati herapeutics (MRTX) along with companies with strong chemistry such Incyte Corporation (INCY) and Exelixis (EXEL).

ARRY

Array BioPharma

$46.42

16.83 (56.88%)

PFE

Pfizer

$42.87

0.12 (0.28%)

MRTX

Mirati Therapeutics

$100.40

6.19 (6.57%)

AGIO

Agios Pharmaceuticals

$50.67

2.7 (5.63%)

INCY

Incyte

$81.84

4.085 (5.25%)

EXEL

Exelixis

$20.65

0.96 (4.88%)

  • 20

    Jun

  • 21

    Jun

  • 28

    Aug

  • 16

    Sep

ARRY Array BioPharma
$46.42

16.83 (56.88%)

06/18/19
LEER
06/18/19
DOWNGRADE
LEER
Market Perform
Array BioPharma downgraded to Market Perform from Outperform at SVB Leerink
06/17/19
JPMS
06/17/19
NO CHANGE
JPMS
Neutral
Array BioPharma 'no bargain' but a clear fit for Pfizer, says JPMorgan
After Pfizer (PFE) announced a $11.4B deal to buy Array BioPharma (ARRY), JPMorgan analyst Christopher Schott said the deal was "no bargain," given that prices for mid-cap biotech are "far from inexpensive," but he sees Array as a logical addition to Pfizer's new launch portfolio. Braftovi/Mektovi, the lead asset for Array, has strong data in melanoma and more recently second and third line metastatic colorectal cancer along with greater than 30 ongoing clinical trials, noted Schott. He expects Pfizer to remain active in looking to complement its internal pipeline with external assets given the "fairly sizable" patent expiration cycle it faces in the mid-to-late 2020s, added the analyst, who keeps a Neutral rating on Pfizer shares.
06/17/19
JEFF
06/17/19
DOWNGRADE
Target $48
JEFF
Hold
Array BioPharma downgraded to Hold from Buy at Jefferies
Jefferies analyst Eun Yang downgraded Array BioPharma (ARRY) to Hold from Buy and raised the price target on the stock to $48 from $30 after the company agreed to be acquired by Pfizer (PFE).
06/17/19
GSCO
06/17/19
NO CHANGE
Target $38
GSCO
Neutral
Array BioPharma price target raised to $38 from $27 at Goldman Sachs
Goldman Sachs analyst Paul Choi raised his price target on Array Biopharma (ARRY) shares to $38 from $27 after Pfizer (PFE) announced plans to acquire the company for $48 per share in an all cash transaction. Choi noted that there is relatively limited overlap, given that Pfizer does not currently have targeted oncology assets in either of the melanoma and colorectal cancer indications Array is approved for or pursuing for the Braftovi/Mektovi combination. Choi maintains a Neutral rating on Array shares.
PFE Pfizer
$42.87

0.12 (0.28%)

06/17/19
WELS
06/17/19
DOWNGRADE
WELS
Market Perform
Array BioPharma downgraded to Market Perform from Outperform at Wells Fargo
Wells Fargo analyst Jim Birchenough downgraded Array Biopharma (ARRY) to Market Perform from Outperform after the company agreed to be acquired by Pfizer (PFE), stating that the latter agreed to pay a "fair premium" in the deal.
06/17/19
STFL
06/17/19
NO CHANGE
STFL
Stifel would be surprised if another suitor tries to outbid Pfizer for Array
After Pfizer (PFE) announced an agreement to acquire Array BioPharma (ARRY) for $48 per share in cash, Stifel analyst Stephen Willey said he views the deal as a "fitting," "logical" and "appropriate" conclusion for Array shareholders and he would be "very surprised" if another suitor tried to compete with a higher priced offer. He believes a "very fair valuation" is implied by the $11.4B price Pfizer has agreed to pay, Willey added. He also sees the deal announcement providing a tailwind for the sector, specifically for small-to-mid cap oncology companies that are "perceived to have achieved some meaningful level of de-risking." As examples, he offers Exelixis (EXEL) and Blueprint Medicines (BPMC), though Willey added that a potentially shortened exclusivity runway could make a deal for Exelixis "a bit harder for a strategic to rationalize."
06/14/19
MAXM
06/14/19
INITIATION
Target $6
MAXM
Buy
Achieve Life Sciences initiated with a Buy at Maxim
Maxim analyst Jason McCarthy initiated Achieve Life Sciences (ACHV) with a Buy rating and a price target of $6, citing the company's development of a "de-risked" smoking cessation aid cytisinicline. The analyst notes that cytisinicline has been in the Eastern European market since the 1970's but has also recently gained "proof of concept" data with a positive phase 2b study of 54% abstinence following 3mg daily intake vs. 16% for placebo. McCarthy adds that Pfizer's (PFE) competing Chantix generated $838M in revenue in FY18 but covered only about 3% of the U.S. smoking population.
MRTX Mirati Therapeutics
$100.40

6.19 (6.57%)

06/07/19
GUGG
06/07/19
DOWNGRADE
GUGG
Neutral
Guggenheim downgrades Mirati to Neutral following near-tripling of stock
As previously reported, Guggenheim analyst Michael Schmidt downgraded Mirati Therapeutics (MRTX) to Neutral from Buy, noting that the shares have nearly tripled since data were presented at the European Society for Medical Oncology, or ESMO, meeting in October. While Schmidt said Amgen's (AMGN) KRAS inhibitor Phase I data presented at the American Society of Clinical Oncology meeting validates MRTX849's potential mechanism of action, he sees a "lot of upside" priced in at the current valuation despite the remaining development risks. He also believes investor expectations have significantly increased ahead of Mirati's own Phase I data presentation in the second half of the year.
06/05/19
LEHM
06/05/19
NO CHANGE
Target $123
LEHM
Overweight
Mirati Therapeutics price target raised to $123 from $85 at Barclays
Barclays analyst Gena Wang raised her price target for Mirati Therapeutics (MRTX) to $123 from $85 saying Amgen's (AMGN) AMG510 data support KRAS G12C as a validated target, and the "impressive" data provide proof of concept for potentially single agent activity in non-small cell lung cancer. The analyst continues to believe that Mirati's MRTX849 could have a more favorable profile based on the preclinical results, including "longer half-life and good tissue penetration." She reiterates an Overweight rating on Mirati Therapeutics.
06/05/19
HCWC
06/05/19
NO CHANGE
Target $117
HCWC
Buy
Mirati Therapeutics price target raised to $117 from $84 at H.C. Wainwright
H.C. Wainwright analyst Edward White raised his price target for Mirati Therapeutics (MRTX) to $117 from $84 saying the positive data for Amgen's (AMGN) AMG 510 bode well for Mirati's MRTX849. The analyst believes the AMG 510 data "somewhat derisks" the development of MRTX849/ He raised his estimate for probability of success for MRTX849 to 20% from 10% and keeps a Buy rating on Mirati Therapeutics.
06/07/19
GUGG
06/07/19
DOWNGRADE
GUGG
Neutral
Mirati Therapeutics downgraded to Neutral from Buy at Guggenheim
Guggenheim analyst Michael Schmidt downgraded Mirati Therapeutics to Neutral from Buy. The analyst sees a "less compelling" risk/reward following the recent rally in the shares.
AGIO Agios Pharmaceuticals
$50.67

2.7 (5.63%)

02/20/19
02/20/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Kodiak Sciences (KOD) initiated with a Buy at Chardan. 2. Veeva (VEEV) initiated with an Equal Weight at Barclays. 3. Agios Pharmaceuticals (AGIO) assumed with a Perform at Oppenheimer. 4. OrthoPediatrics (KIDS) initiated with an Outperform at JMP Securities. 5. Homology Medicines (FIXX) initiated with a Buy at H.C. Wainwright. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
05/03/19
PIPR
05/03/19
NO CHANGE
Target $85
PIPR
Overweight
Agios Pharmaceuticals price target lowered to $85 from $100 at Piper Jaffray
Piper Jaffray analyst Tyler Van Buren lowered his price target for Agios Pharmaceuticals to $85 from $100 after Tibsovo sales came in below expectations for Q1. However, the analyst says this appears to be due to seasonality and that the strength of the underlying commercial efforts gives him confidence that the launch will return to its original trajectory. Van Buren keeps an Overweight rating on Agios shares.
05/16/19
RBCM
05/16/19
NO CHANGE
Target $90
RBCM
Outperform
Agios Pharmaceuticals price target raised to $90 from $85 at RBC Capital
RBC Capital analyst Kennen MacKay raised his price target on Agios Pharmaceuticals to $90, saying the company's "successful" results in Phase 3 ClarIDHy trial for Tibsovo in cholangiocarcinoma have de-risked that indication and removed the overhang on the stock. The analyst contends that the findings set up the stock for upside in the back half of the year, adding that Agios Pharma's Phase 3 Mitapivat data in 2020 also position Tibsovo as an "underappreciated potentially blockbuster rare-disease drug."
05/23/19
GSCO
05/23/19
INITIATION
Target $55
GSCO
Neutral
Agios Pharmaceuticals assumed with a Neutral at Goldman Sachs
Goldman Sachs analyst Salveen Richter assumed coverage of Agios Pharmaceuticals with a Neutral rating and $55 price target. The firm previously had a Neutral rating on the shares.
INCY Incyte
$81.84

4.085 (5.25%)

05/21/19
05/21/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Uber (UBER) initiated with an Equal Weight at Consumer Edge and a Neutral at Susquehanna. 2. Incyte (INCY) initiated with a Neutral at Credit Suisse. 3. Hillenbrand (HI) initiated with a Neutral at DA Davidson. 4. Target Hospitality (TH) initiated with a Buy at Deutsche Bank. 5. Jack in the Box (JACK) reinstated with an Equal Weight at Morgan Stanley. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
05/20/19
FBCO
05/20/19
INITIATION
Target $75
FBCO
Neutral
Incyte initiated with a Neutral at Credit Suisse
Credit Suisse analyst Evan Seigerman started Incyte with a Neutral rating and $75 price target. The analyst wants to see more clinical evidence and trial execution in the company's its pipeline following last year's failure of epacadostat before coming more positive on the stock.
06/17/19
PIPR
06/17/19
NO CHANGE
PIPR
Overweight
Incyte congress presentations reinforce Piper's enthusiam for ruxolitinib cream
Piper Jaffray analyst Tyler Van Buren said Incyte reported positive updates for the topical ruxolitinib programs in vitiligo and atopic dermatitis at the World Congress of Dermatology, which he said "further reinforce" the enthusiasm he has about the product candidate. In the data presented at the meeting, ruxolitinib demonstrated "impressive" activity in vitiligo and "solid efficacy" in atopic dermatitis out to 12 weeks, said Van Buren, who thinks the drug could generate over $1B in global sales by the late 2020s for its combined eventual indications. He keeps an Overweight rating on Incyte shares.
05/15/19
PIPR
05/15/19
NO CHANGE
Target $95
PIPR
Overweight
Incyte price target raised to $95 from $85 at Piper Jaffray
Piper Jaffray analyst Tyler Van Buren raised his price target for Incyte to $95 from $85 and reiterates an Overweight rating on the shares. The analyst models a U.S. atopic dermatitis and vitiligo launch in 2021 and 2023, respectively, with combined global sales surpassing $1B by the late 2020s. Incyte is "fully capable" of launching topical Jakafi in these indications with a specialty sales force of a couple hundred people, Van Buren tells investors in a research note. Further, the analyst notes that a key opinion leader Piper hosted was "very bullish" on topical Jakafi. The doctor believes that the efficacy of topical Jakafi exceeds that of the currently available non-steroidals, says Van Buren.
EXEL Exelixis
$20.65

0.96 (4.88%)

03/18/19
MSCO
03/18/19
UPGRADE
Target $28
MSCO
Equal Weight
Morgan Stanley sees limited downside risk for Exelixis, upgrades to Equal Weight
As previously reported, Morgan Stanley analyst Jeffrey Hung upgraded Exelixis to Equal Weight from Underweight, citing his view there is limited downside risk for the stock ahead of the cabozantinib/nivolumab data from CheckMate 9ER later this year. Additionally, cabozantinib scripts are looking better in 2019 and Hung sees multiple ways this trend could continue, he tells investors. Hung raised his price target on Exelixis shares to $28 from $20.
03/18/19
MSCO
03/18/19
UPGRADE
MSCO
Equal Weight
Exelixis upgraded to Equal Weight from Underweight at Morgan Stanley
03/01/19
PIPR
03/01/19
NO CHANGE
Target $48
PIPR
Overweight
Exelixis price target raised to $48 from $26 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff raised his price target for Exelixis to $48 after taking a closer look at the company's bottom-line including breaking out non-cash expenses. The analyst projects U.S. Cabometyx sales to grow from $600M in 2018, to $826M in 2019 and $1.07B in 2020. Factoring in a 22% projected tax rate, he forecasts GAAP net income of $300M, or 95c per diluted share, in 2019 to increase to $375M or $1.17, in 2020. Backing out non-cash stock comp and federal taxes, the analyst projects Non-GAAP net income to grow from $431M or $1.37 per diluted share in 2019 to $532M or $1.66 in 2020. Tenthoff reiterates an Overweight rating on Exelixis.

TODAY'S FREE FLY STORIES

RARX

RA Pharmaceuticals

$36.01

2.42 (7.20%)

17:29
07/22/19
07/22
17:29
07/22/19
17:29
Syndicate
RA Pharmaceuticals files to sell $100M of common stock »

Jefferies, BMO Capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BHE

Benchmark Electronics

$25.05

0.22 (0.89%)

17:29
07/22/19
07/22
17:29
07/22/19
17:29
Hot Stocks
Benchmark Electronics appoints Rob Crawford Chief Revenue Officer »

Benchmark Electronics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

AAPL

Apple

$207.21

4.59 (2.27%)

, INTC

Intel

$51.36

1.1 (2.19%)

17:28
07/22/19
07/22
17:28
07/22/19
17:28
Periodicals
Apple may pay $1B or more for Intel patents, staff in chip unit deal, WSJ says »

Apple (AAPL) is in…

AAPL

Apple

$207.21

4.59 (2.27%)

INTC

Intel

$51.36

1.1 (2.19%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 30

    Jul

  • 03

    Aug

ATVI

Activision Blizzard

$45.57

0.43 (0.95%)

17:26
07/22/19
07/22
17:26
07/22/19
17:26
Hot Stocks
Blizzard co-founder Frank Pearce departing after 28 years »

One of the founders of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Aug

  • 05

    Sep

NBSE

NeuBase Therapeutics

$3.55

-0.58 (-14.04%)

17:25
07/22/19
07/22
17:25
07/22/19
17:25
Hot Stocks
Carnegie Mellon reports 5.5% passive stake in NeuBase Therapeutics »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CADE

Cadence Bancorp

$15.86

-3.75 (-19.12%)

17:23
07/22/19
07/22
17:23
07/22/19
17:23
Downgrade
Cadence Bancorp rating change  »

Cadence Bancorp…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jul

  • 06

    Aug

  • 26

    Aug

  • 23

    Sep

CAL

Caleres

$18.27

0.27 (1.50%)

17:22
07/22/19
07/22
17:22
07/22/19
17:22
Hot Stocks
Caleres, Veronica Beard announce exclusive footwear partnership »

Caleres and Veronica…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

AAPL

Apple

$207.21

4.59 (2.27%)

, INTC

Intel

$51.36

1.1 (2.19%)

17:22
07/22/19
07/22
17:22
07/22/19
17:22
Periodicals
Breaking Periodicals news story on Apple, Intel »

Apple in advanced talks…

AAPL

Apple

$207.21

4.59 (2.27%)

INTC

Intel

$51.36

1.1 (2.19%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 30

    Jul

  • 03

    Aug

EFSC

Enterprise Financial

$39.39

-0.58 (-1.45%)

17:19
07/22/19
07/22
17:19
07/22/19
17:19
Earnings
Enterprise Financial reports Q2 EPS 98c, consensus 93c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

TTEC

TTEC Holdings

$47.31

0.04 (0.08%)

17:19
07/22/19
07/22
17:19
07/22/19
17:19
Syndicate
Breaking Syndicate news story on TTEC Holdings »

TTEC Holdings files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Aug

TTEC

TTEC Holdings

$47.31

0.04 (0.08%)

17:18
07/22/19
07/22
17:18
07/22/19
17:18
Syndicate
Breaking Syndicate news story on TTEC Holdings »

TTEC Holdings files $350M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Aug

VBTX

Veritex

$25.67

-0.44 (-1.69%)

17:17
07/22/19
07/22
17:17
07/22/19
17:17
Earnings
Veritex reports Q2 EPS 59c, consensus 62c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 26

    Aug

  • 23

    Sep

WM

Waste Management

$117.15

0.39 (0.33%)

17:12
07/22/19
07/22
17:12
07/22/19
17:12
Initiation
Waste Management initiated  »

Waste Management…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

IBTX

Independent Bank

$55.08

-1.08 (-1.92%)

17:05
07/22/19
07/22
17:05
07/22/19
17:05
Earnings
Independent Bank reports Q2 adjusted EPS $1.22, consensus $1.27 »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 26

    Aug

  • 23

    Sep

RNST

Renasant

$34.10

-0.49 (-1.42%)

17:04
07/22/19
07/22
17:04
07/22/19
17:04
Earnings
Renasant reports Q2 EPS 80c with items, consensus 81c »

Reports Q2 net loan…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 23

    Sep

STLD

Steel Dynamics

$31.55

0.09 (0.29%)

17:03
07/22/19
07/22
17:03
07/22/19
17:03
Hot Stocks
Steel Dynamics announces planned new flat roll steel mill site selection »

Steel Dynamics announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 06

    Aug

BRO

Brown & Brown

$34.64

-0.11 (-0.32%)

17:02
07/22/19
07/22
17:02
07/22/19
17:02
Hot Stocks
Brown & Brown reports Q2 organic revenue up 3.9% »

Reports Q2 EBITDA margin…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

HAE

Haemonetics

$122.44

0.35 (0.29%)

17:02
07/22/19
07/22
17:02
07/22/19
17:02
Hot Stocks
Haemonetics updates financial reporting segments »

Haemonetics Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 06

    Aug

  • 05

    Sep

  • 09

    Sep

BRO

Brown & Brown

$34.64

-0.11 (-0.32%)

17:01
07/22/19
07/22
17:01
07/22/19
17:01
Earnings
Brown & Brown reports Q2 adjusted EPS 32c, consensus 28c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

DLX

Deluxe

$41.95

0.41 (0.99%)

17:00
07/22/19
07/22
17:00
07/22/19
17:00
Hot Stocks
Deluxe names Chris Thomas chief revenue officer »

Deluxe Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 19

    Sep

GE

General Electric

$10.22

0.18 (1.79%)

, AVCO

Avalon GloboCare

$2.05

-0.105 (-4.88%)

16:57
07/22/19
07/22
16:57
07/22/19
16:57
Hot Stocks
Avalon GloboCare and GE Healthcare announce strategic partnership »

Avalon GloboCare (AVCO)…

GE

General Electric

$10.22

0.18 (1.79%)

AVCO

Avalon GloboCare

$2.05

-0.105 (-4.88%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jul

  • 09

    Sep

  • 09

    Sep

VIVE

Viveve

$0.41

-0.0155 (-3.68%)

16:55
07/22/19
07/22
16:55
07/22/19
16:55
Hot Stocks
Breaking Hot Stocks news story on Viveve 

Viveve trading resumes

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VFF

Village Farms

$10.69

0.48 (4.70%)

16:53
07/22/19
07/22
16:53
07/22/19
16:53
Initiation
Village Farms initiated at Craig-Hallum »

Village Farms initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BBY

Best Buy

$75.72

0.995 (1.33%)

16:53
07/22/19
07/22
16:53
07/22/19
16:53
Hot Stocks
Best Buy beneficial owner Richard Schulze sells $32.4M in company shares »

Best Buy beneficial owner…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Aug

ORGO

Organogenesis

$5.85

-0.27 (-4.41%)

16:50
07/22/19
07/22
16:50
07/22/19
16:50
Syndicate
Organogenesis commences exchange offer »

Organogenesis Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Aug

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.